登录    
  
首页 > 期刊论文 > 论文摘要
化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性
         
Treatment outcomes and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib (as second-line treatment)-resistant advanced non-small cell lung cancer

摘    要
目的: 观察二线厄洛替尼耐药后应用化疗序贯厄洛替尼治疗晚期非小细胞肺癌的疗效和安全性。方法: 回顾性分析30例ⅢB~Ⅳ期二线厄洛替尼耐药后缓慢进展的晚期非小细胞肺癌患者的资料,其中15例接受1个周期化疗(培美曲塞联合顺铂)后序贯厄洛替尼治疗(A组),另15例仅接受化疗(培美曲塞联合顺铂)(B组)。观察两组的近期疗效和不良反应,并进行生存分析。结果: A组和B组的客观缓解率分别为13.3%(2/15)和6.7%(1/15)(P=1.000),疾病控制率分别为40.0%(6/15)和20.0%(3/15)(P=0.426),中位无进展生存期分别为6.0和4.0个月(P=0.001)。两组不良反应发生率差异无统计学意义。结论: 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌患者具有较好的疗效,且不良反应可以耐受。
标    签   非小细胞肺   厄洛替尼   抗肿瘤联合化疗方案   耐药   治疗结果   Carcinoma   non-small cell lung   Erlotinib   Antineoplastic combined chemotherapy protocol   Resistance   Treatment outcomes  
 
Abstract
Objective: To observe the therapeutic efficacy and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib (as second-line treatment)-resistant advanced NSCLC (non-small cell lung cancer).Methods: Thirty stages ⅢB-Ⅳ NSCLC patients with gradual progression after erlotinib treatment as second-line therapy were retrospectively reviewed. Of the 30 patinets, 15 patinets (group A) received one cycle of chemotherapy (pemetrexed plus cisplatin) followed by erlotinib, the remaining 15 patinets (group B) received chemotherapy alone (pemetrexed plus cisplatin). The short-term response and side effects were observed and the survival was analyzed.Results: The objective response rates of group A and group B were 13.3% (2/15) and 6.7% (1/15), respectively (P=1.000), and the disease control rates were 40.0% (6/15) and 20.0% (3/15), respectively (P=0.426). The median progression-free survival of group A and group B were 6.0 and 4.0 months, respectively (P=0.001). There were no significant differences in the rates of side effects between the two groups.Conclusion: The administration of erlotinib following chemotherapy may offer benefits to the patients with erlotinib (as second-line treatment)-resistant advanced NSCLC. This treatment is also generally tolerable.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2013.11.011

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床研究

基金项目

收稿日期 2013/6/4

修改稿日期 2013/8/13

网络出版日期

作者单位点击查看


引用该论文: YU Xue-juan,ZHANG Pin-liang,LIU Zeng-jun,LIU Ying,LI Ming,XU Ni,REN Rui-mei. Treatment outcomes and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib (as second-line treatment)-resistant advanced non-small cell lung cancer[J]. Tumor, 2013, 33(11): 1002~1007
于学娟,张品良,刘增军,刘颖,李明,徐妮,任瑞美. 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性[J]. 肿瘤, 2013, 33(11): 1002~1007


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】AZZOLI C G, BAKER S J R, TEMIN S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stageⅣ non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(36):6251-6266.
 
【2】ETTINGER D S, AKERLEY W, BEPLER G, et al. Nonsmall cell lung cancer[J]. J Natl Compr Canc Netw, 2010, 8(7):740-801.
 
【3】GAUGHAN E M, COSTA D B. Genotype-driven therapies for non-small cell lung cancer:focus on EGFR, KRAS and ALK gene abnormalities[J]. Ther Adv Med Oncol, 2011, 3(3):113-125.
 
【4】KIM E S, HIRSH V, MOK T, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST):a randomised phaseⅢ trial[J]. Lancet, 2008, 372(9652):1809-1818.
 
【5】CAPPUZZO F, CIULEANU T, STELMAKH L, et al. Erlotinib as maintenance treatment in advanced non-small cell lung cancer:a multicentre, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2010,11(6):521-529.
 
【6】HERBST R S, GIACCONE G, SCHILLER J H, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial——INTACT 2[J]. J Clin Oncol, 2004, 22(5):785-794.
 
【7】GATZEMEIER U, PLUZANSKA A, SZCZESNA A, et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer:the Tarceva Lung Cancer Investigation Trial[J]. J Clin Oncol, 2007, 25(12):1545-1552.
 
【8】MUMENTHALER S M, FOO J, LEDER K, et al. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer[J]. Mol Pharm, 2011, 8(6):2069-2079.
 
【9】DAVIES A M, HO C, BECKETT L, et al. Intermittent erlotinib in combination with pemetrexed:phaseⅠschedules designed to achieve pharmacodynamic separation[J]. J Thorac Oncol, 2009, 4(7):862-868.
 
【10】FURY M G, SOLIT D B, SU Y B, et al. A phaseⅠtrial of intermittent high-dose gefitinib and fixeddose docetaxel in patients with advanced solid tumors[J]. Cancer Chemother Pharmacol, 2007, 59(4):467-475.
 
【11】RIELY G J, RIZVI N A, KRIS M G, et al. Randomized phaseⅡ study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(2):264-270.
 
【12】YANG J J, CHEN H J, YAN H H, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced nonsmall cell lung cancer[J]. Lung Cancer, 2013, 79(1):33-39.
 
【13】EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
 
【14】TROTTI A, BENTZEN S M. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol, 2004, 22(1):19-22.
 
【15】SHEPHERD F A, RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353(2):123-132.
 
【16】KIM Y, KO J, CUI Z, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor[J]. Mol Cancer Ther, 2012, 11(3):784-791.
 
【17】SUDA K, MURAKAMI I, KATAYAMA T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer[J]. Clin Cancer Res, 2010, 16(22):5489-5498.
 
【18】ENGELMAN J A, ZEJNULLAHU K, MITSUDOMI T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827):1039-1043.
 
【19】AYOOLA A, BAROCHIA A, BELANI K, et al. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer:an update[J]. Cancer Invest, 2012, 30(5):433-446.
 
【20】WANG Y S, WANG Y H, XIA H P, et al. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFRmutant cell lines[J]. Asian Pac J Cancer Prev, 2012, 13(1):255-260.
 
【21】BRYANT J L, BRITSON J, BALKO J M, et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT[J]. Br J Cancer, 2012, 106(1):148-156.
 
【22】SUDA K, TOMIZAWA K, FUJII M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib[J]. J Thorac Oncol, 2011, 6(7):1152-1161.
 
【23】王津京, 张为民, 陈蓓, 等. 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用[J]. 肿瘤, 2013, 33(2):103-110.
 
【24】KUO C H, LIN S M, LEE K Y, et al. Subsequent chemotherapy improves survival outcome in advanced non-small cell lung cancer with acquired tyrosine kinase inhibitor resistance[J]. Clin Lung Cancer, 2010,11(1):51-56.
 
【25】FAN Y, HUANG Z Y, YU H F, et al. Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI[J]. Zhonghua Zhong Liu Za Zhi, 2010, 32(11):859-863.
 
【26】安彤同, 黄真, 王玉艳, 等. 晚期非小细胞肺癌初始治疗后再次应用EGFR-TKI的疗效观察[J]. 中国肺癌杂志, 2011,14(3):261-265.
 
【27】MIYAMOTO S, OHKUMA Y, TAKAGI Y, et al. Retreatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) for lung adenocarcinoma[J]. Gan To Kagaku Ryoho, 2010, 37(10):1907-1911.
 
【28】WANG Y, ZHANG J, LIU H, et al. Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small cell lung cancer[J]. Clin Drug Investig, 2011, 31(4):279-283.
 
相关信息
   标题 相关频次
 基于PET/CT影像的大分割后程加速三维适形放疗与常规分割放疗治疗局部晚期非小细胞肺癌的前瞻性随机对照研究
 10
 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察
 6
 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
 5
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4
 腺相关病毒介导的肝细胞生长因子Kringle 1结构域对人前列腺癌裸鼠骨移植瘤生长的影响
 4
 多靶点受体酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的Meta分析
 3
 厄罗替尼一线治疗中晚期非小细胞肺癌老年患者的临床观察
 3
 非小细胞肺癌CD44v6表达的免疫组化研究
 3
 晚期非小细胞肺癌个体化化疗联合中药治疗:一项随机对照试验
 3
 2009年恶性肿瘤临床治疗新进展
 2
 28例宫颈癌放疗后主动脉旁淋巴结转移的调强放射治疗
 2
 34例卵巢透明细胞癌临床分析
 2
 Autotaxin在人卵巢癌基因及蛋白水平表达的研究及意义
 2
 C-myc蛋白在睾丸肿瘤中的表达及意义
 2
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 2
 miRNA-200c逆转胃癌SGC7901/DDP细胞对顺铂的耐药性及其相关机制
 2
 Mito-FLAG方案治疗难治/复发急性髓细胞白血病的临床观察
 2
 PPARγ的配体15d-PGJ2对人类胃癌细胞生长的影响
 2
 VDZ方案治疗多发性骨髓瘤疗效观察
 2
 癌症的远古性及其理论和实践意义
 2
 靶向内皮细胞糖酵解限速酶PFKFB3的抗肿瘤血管生成研究进展
 2
 白蛋白结合型紫杉醇治疗晚期乳腺癌的临床观察
 2
 膀胱移行细胞癌中cPKCα的表达及意义
 2
 表达FasL的肝癌细胞通过Fas/FasL诱导T淋巴细胞发生凋亡
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2